rSIFN-co

Drug Profile

rSIFN-co

Alternative Names: Crystalline recombinant interferon; Recombinant super compound interferon; Recombinant super interferon compound

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Sichuan Huiyang Life Science and Technology Corporation
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jan 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (SC) (NCT02464007)
  • 07 Dec 2015 No recent reports on development identified - Phase-III for Solid tumours in China (SC)
  • 24 Jun 2015 Sichuan Huiyang Life Science and Technology Corporation plans a phase I trial for Solid tumours (Late-stage disease) in USA (NCT02464007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top